GUARDANT HEALTH INC (GH) Stock Price & Overview

NASDAQ:GH • US40131M1099

Current stock price

84.61 USD
-3.49 (-3.96%)
At close:
84.61 USD
0 (0%)
After Hours:

The current stock price of GH is 84.61 USD. Today GH is down by -3.96%. In the past month the price decreased by -9.89%. In the past year, price increased by 96.13%.

GH Key Statistics

52-Week Range36.36 - 120.74
Current GH stock price positioned within its 52-week range.
1-Month Range82.26 - 96.52
Current GH stock price positioned within its 1-month range.
Market Cap
11.098B
P/E
N/A
Fwd P/E
N/A
EPS (TTM)
-3.36
Dividend Yield
N/A

GH Stock Performance

Today
-3.96%
1 Week
-0.67%
1 Month
-9.89%
3 Months
-17.84%
Longer-term
6 Months +40.95%
1 Year +96.13%
2 Years +310.13%
3 Years +260.96%
5 Years -44.57%
10 Years N/A

GH Stock Chart

GUARDANT HEALTH INC / GH Daily stock chart

GH Technical Analysis

ChartMill assigns a technical rating of 3 / 10 to GH. When comparing the yearly performance of all stocks, GH is one of the better performing stocks in the market, outperforming 90.2% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

GH Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to GH. While GH seems to be doing ok healthwise, there are quite some concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

GH Earnings

On February 19, 2026 GH reported an EPS of -1 and a revenue of 281.27M. The company missed EPS expectations (-38.56% surprise) and beat revenue expectations (0.76% surprise).

Next Earnings DateApr 28, 2026
Last Earnings DateFeb 19, 2026
PeriodQ4 / 2025
EPS Reported-$1.00
Revenue Reported281.266M
EPS Surprise -38.56%
Revenue Surprise 0.76%

GH Forecast & Estimates

34 analysts have analysed GH and the average price target is 132.26 USD. This implies a price increase of 56.32% is expected in the next year compared to the current price of 84.61.

For the next year, analysts expect an EPS growth of 17.14% and a revenue growth 31% for GH


Analysts
Analysts85.88
Price Target132.26 (56.32%)
EPS Next Y17.14%
Revenue Next Year31%

GH Groups

Sector & Classification

GH Financial Highlights

Over the last trailing twelve months GH reported a non-GAAP Earnings per Share(EPS) of -3.36. The EPS increased by 5.62% compared to the year before.


Income Statements
Revenue(TTM)982.02M
Net Income(TTM)-416.28M
Industry RankSector Rank
PM (TTM) N/A
ROA -20.67%
ROE N/A
Debt/Equity N/A
Chartmill High Growth Momentum
EPS Q2Q%-11.11%
Sales Q2Q%39.37%
EPS 1Y (TTM)5.62%
Revenue 1Y (TTM)32.88%

GH Ownership

Ownership
Inst Owners100.86%
Shares131.17M
Float125.73M
Ins Owners3.99%
Short Float %8.72%
Short Ratio5.37

About GH

Company Profile

GH logo image Guardant Health, Inc. is a precision oncology company, which engages in the provision of treatment of cancer through the use of proprietary blood-based tests, vast data sets, and advanced analytics. The company is headquartered in Palo Alto, California and currently employs 2,490 full-time employees. The company went IPO on 2018-10-04. The company provides critical insights into what drives disease through its advanced blood and tissue tests, real-world data, and artificial intelligence (AI) analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and helping doctors select the treatment for patients with advanced cancer. For patients with advanced-stage cancer, it has developed Guardant360 laboratory developed test (LDT), and Guardant360 CDx test, a comprehensive liquid biopsy test to provide tumor mutation profiling with solid tumors and to be used as a companion diagnostic in connection with non-small cell lung cancer (NSCLC), and breast cancer. The company offers other tests, including Guardant360 Tissue test, Guardant Reveal blood test, Guardant360 Response blood test and others.

Company Info

IPO: 2018-10-04

GUARDANT HEALTH INC

3100 Hanover Street

Palo Alto CALIFORNIA 94063 US

CEO: Helmy Eltoukhy

Employees: 2490

GH Company Website

GH Investor Relations

Phone: 18556988887

GUARDANT HEALTH INC / GH FAQ

What does GUARDANT HEALTH INC do?

Guardant Health, Inc. is a precision oncology company, which engages in the provision of treatment of cancer through the use of proprietary blood-based tests, vast data sets, and advanced analytics. The company is headquartered in Palo Alto, California and currently employs 2,490 full-time employees. The company went IPO on 2018-10-04. The company provides critical insights into what drives disease through its advanced blood and tissue tests, real-world data, and artificial intelligence (AI) analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and helping doctors select the treatment for patients with advanced cancer. For patients with advanced-stage cancer, it has developed Guardant360 laboratory developed test (LDT), and Guardant360 CDx test, a comprehensive liquid biopsy test to provide tumor mutation profiling with solid tumors and to be used as a companion diagnostic in connection with non-small cell lung cancer (NSCLC), and breast cancer. The company offers other tests, including Guardant360 Tissue test, Guardant Reveal blood test, Guardant360 Response blood test and others.


What is the current price of GH stock?

The current stock price of GH is 84.61 USD. The price decreased by -3.96% in the last trading session.


Does GH stock pay dividends?

GH does not pay a dividend.


What is the ChartMill rating of GUARDANT HEALTH INC stock?

GH has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 3 out of 10.


What do analysts say about GUARDANT HEALTH INC (GH) stock?

34 analysts have analysed GH and the average price target is 132.26 USD. This implies a price increase of 56.32% is expected in the next year compared to the current price of 84.61.


What is the employee count for GH stock?

GUARDANT HEALTH INC (GH) currently has 2490 employees.